STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
Russell Angus C.

2. Issuer Name and Ticker or Trading Symbol
QUESTCOR PHARMACEUTICALS INC [ QCOR ]

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2014

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director
10% Owner
Officer (give title below)

6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 4)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/14/2014</td>
<td></td>
<td></td>
<td>(1)</td>
<td>4,529</td>
<td>(1)</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/14/2014</td>
<td></td>
<td></td>
<td>(1)</td>
<td>3,835</td>
<td>(2)</td>
<td>D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (right to buy)</td>
<td>$36.29</td>
<td>08/14/2014</td>
<td></td>
<td>(2)</td>
<td>3,281</td>
<td>(3)</td>
<td>(4)</td>
<td>06/07/2023</td>
<td>Common Stock</td>
<td>3,281</td>
<td>(3)</td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. Pursuant to Agreement and Plan of Merger, dated April 5, 2014 (the “Merger Agreement”), by and among Mallinckrodt plc (“Mallinckrodt”), Quincy Merger Sub, Inc. and Questcor Pharmaceuticals, Inc. (“Questcor”), Mallinckrodt acquired Questcor in a merger transaction (the “Merger”) which closed at 4:30 p.m. EST, on August 14, 2014 (the “Effective Time”). At the Effective Time, each share of Questcor common stock (except for certain shares defined in the Merger Agreement) converted into the right to receive, without interest, (a) $30.00 in cash and (b) 0.897 of an ordinary share of Mallinckrodt, in exchange for such share of Questcor common stock (“Merger Consideration”).

2. Pursuant to terms of the Merger, each outstanding Questcor restricted stock award held by Questcor non-employee directors will be cancelled and converted into the right to receive Merger Consideration in respect of each share of Questcor common stock underlying the Questcor restricted stock award.

3. Pursuant to terms of the Merger, at the Effective Time, Questcor stock option, whether vested or unvested, held by Questcor non-employee directors converted into the right to receive the Merger Consideration with respect to each share of Questcor common stock subject to such option immediately prior to the effective time of the Merger, net of the applicable exercise price.

4. Fully exercisable.

Remarks:

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.